Singapore, 7 May 2026 — SDAI Limited (“SDAI” or the “Company”), a Catalist-listed entity on the Singapore Exchange, has made a significant move towards transforming its core business. At the extraordinary general meeting held on 30 April 2026, shareholders granted approval for the Company’s proposed diversification into the fast-growing biotechnology industry, marking a pivotal shift in its corporate strategy and positioning SDAI at the forefront of Asia’s burgeoning anti-ageing and longevity healthcare market.
Key Highlights of the Report
- Shareholder Approval for Diversification: SDAI has received the green light from its shareholders to expand its business focus beyond its traditional core activities to include biotechnology, with an emphasis on anti-ageing and longevity healthcare products and services.
- Major Industry Growth Potential: The global anti-ageing market, valued at US\$80 billion in 2025, is projected to grow to US\$84.4 billion in 2026 and reach US\$137.1 billion by 2035, representing a CAGR of 5.5%. The Singapore government’s RIE2030 Plan, with an investment of S\$37 billion from April 2026, further underpins this sector’s growth by prioritizing healthy and successful longevity research.
- Strategic Initiatives and Partnerships:
- Entered a strategic cooperation with LiveBeyond Pte. Ltd. to jointly develop and apply anti-ageing and longevity solutions. LiveBeyond is known for translating cutting-edge longevity research (including biological age diagnostics, healthspan biomarkers, regenerative medicine, and therapeutics) into scalable medical solutions.
- Launched the Bluecode Biotech B-III skincare series in China and Singapore, leveraging advanced bioengineering and plant stem cell technology to rejuvenate skin by restoring cell-to-cell communication.
- Formed a joint venture with Hubei Qiai Group Co., Ltd. and QCM Holdings Pte. Ltd. to expand the moxibustion product market in ASEAN, including the opening of the first moxibustion experience centre in Singapore.
- Proprietary Competitive Advantage: SDAI’s technology platform integrates modern scientific advancements with traditional herbal remedies, creating tailored anti-ageing solutions for Asian populations. This approach addresses genetic and lifestyle differences often overlooked by Western-developed products, securing SDAI a defensible market position.
- Industry Recognition: The Company was awarded “Best Biotechnology Healthcare Solutions Development 2026 – Asia Pacific” by APAC Insider’s South East Asia Business Awards, underscoring its strength and leadership in the sector.
- Diversification Benefits: The biotechnology expansion is expected to generate new revenue streams, mitigate business risks, enable geographical diversification across multiple markets, and afford greater flexibility and efficiency in executing future biotech-related transactions.
- Clear Focus on Growth Pillars: SDAI will now concentrate on three core business areas: skin anti-ageing products, anti-ageing supplements and solutions, and mugwort-based moxibustion health management.
- Commitment to Long-Term Value: The Executive Chairperson, Madam Hao Dongting, emphasized the Group’s aim to establish a first-mover advantage in Asia’s longevity sector, positioning SDAI as a leading brand in anti-ageing and making healthy longevity a scalable consumer offering.
Important and Potentially Price-Sensitive Information for Shareholders
- Transformation to Biotechnology-Focused Platform: The shareholder-approved shift into biotechnology, coupled with recent strategic collaborations and product launches, could significantly enhance SDAI’s revenue base and market valuation, positioning it as a pioneer in a high-growth sector.
- Access to High-Growth Markets: With Asia’s anti-ageing market expanding rapidly and government-backed research funding, SDAI stands to benefit from early-mover advantages and strong demand for longevity solutions.
- Reduced Regulatory and Execution Risk: The ability to pursue biotech-related transactions without the need for separate general meetings streamlines execution and could fast-track future deals and partnerships.
- Strategic Alliances and Product Innovation: Partnerships with LiveBeyond and Hubei Qiai, plus the launch of the B-III skincare series, signal a robust innovation pipeline and the Company’s intent to capture significant market share in both traditional and modern wellness segments.
- Geographical Expansion: SDAI’s focus on ASEAN and China, supported by physical experience centres, sets the stage for rapid regional growth and increased brand visibility.
- Recognition and Awards: Industry recognition enhances SDAI’s credibility and could catalyse further partnerships, customer acquisition, and investor interest.
Detailed Business Transformation and Forward Strategy
SDAI’s transformation is not merely a sectoral pivot but a comprehensive strategy to capture long-term, sustainable growth. The Company’s proprietary integration of herbal medicine with life sciences is tailored for Asian consumers—a market segment often underserved by global players. The forward-looking strategy focuses on:
- Accelerating R&D and commercialization of advanced, differentiated anti-ageing solutions
- Expanding product offerings and market presence in both skincare and health supplements
- Modernizing traditional wellness practices (e.g., mugwort-based moxibustion) into scalable, accessible consumer products
- Leveraging partnerships to access best-in-class research and distribution networks
The management acknowledges that while the transition is in its early stages and financial results may take time to materialize, the foundations laid in 2025 and 2026—through strategic alliances and the launch of innovative products—have positioned SDAI for accelerated future growth.
Conclusion
For investors, SDAI’s strategic approval to enter the biotechnology sector, coupled with clear execution across product development, partnerships, and market expansion, constitutes a potentially transformative event for the Company. These developments could meaningfully impact SDAI’s future earnings, valuation, and share price, making this a critical juncture for both current and prospective shareholders to monitor closely.
Disclaimer: This article is for informational and reporting purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The information herein is based on corporate disclosures and public announcements and may be subject to change without notice.
View SDAI Historical chart here